期刊
EUROPEAN HEART JOURNAL
卷 33, 期 19, 页码 2388-+出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehs220
关键词
Aortic stenosis; TAVI; TAVR
资金
- Edwards Lifesciences
- St Jude Medical
Surgical aortic valve replacement (SAVR) is currently the standard of care to treat patients with severe symptomatic aortic stenosis (AS) and is generally accepted to alleviate symptoms and prolong survival. Based on the results of randomized trials, transcatheter aortic valve implantation (TAVI) is the new standard of care for patients with symptomatic AS who are deemed oinoperable'. Debatably, TAVI is also an alternative to SAVR in selected patients who are at high risk but operable. As we approach 10 years of clinical experience with TAVI, with over 50 000 implantations in 40 countries, a review of the current literature and clinical outcomes with this rapidly evolving technology is appropriate.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据